Viral Conjunctivitis Treatment Study
| Status: | Recruiting |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/6/2019 |
| Start Date: | November 14, 2018 |
| End Date: | June 1, 2020 |
| Contact: | Andrew J Rong, MD |
| Email: | ajr211@med.miami.edu |
| Phone: | 3053266000 |
Avenova for the Treatment of Viral Conjunctivitis
The objective of this study is to determine the efficacy Avenova® (0.01% hypochlorous acid)
in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated
with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral
Conjunctivitis compared with artificial tears.
in the treatment of viral conjunctivitis. The investigators hypothesize that patients treated
with Avenova® will have a quicker resolution of their ocular signs and symptoms of Viral
Conjunctivitis compared with artificial tears.
Avenova® is a proprietary pure hypochlorous acid under a family of skin cleansing products by
NovaBay that has been cleared by the FDA as a 510(k) medical device. Many in vitro studies
have evaluated the efficacy of hypochlorous acid against microbacterial and viral agents. In
ophthalmology, it is commonly used as a lid cleanser in the treatment of blepharitis and
meibomian gland dysfunction. It is applied directly to the lid margin and has an excellent
skin and ocular safety profile, which includes a lack of ocular irritation on application.The
investigators propose a study to evaluate the role of Avenova® (0.01% hypochlorous acid) in
the treatment of common ocular viral infections.
NovaBay that has been cleared by the FDA as a 510(k) medical device. Many in vitro studies
have evaluated the efficacy of hypochlorous acid against microbacterial and viral agents. In
ophthalmology, it is commonly used as a lid cleanser in the treatment of blepharitis and
meibomian gland dysfunction. It is applied directly to the lid margin and has an excellent
skin and ocular safety profile, which includes a lack of ocular irritation on application.The
investigators propose a study to evaluate the role of Avenova® (0.01% hypochlorous acid) in
the treatment of common ocular viral infections.
Inclusion Criteria:
- Patients presenting to the Bascom Palmer Eye Institute
- Clinical diagnosis of viral conjunctivitis
- Symptoms less than 1 week duration
Exclusion Criteria:
- history of allergic conjunctivitis
- history of herpetic eye disease
- concurrent diagnosis of bacterial conjunctivitis (based off microbiology plating)
- Immunocompromised / Immunosuppressed patients
- Patients with HIV
- pregnant women
- prisoners
- adults who are unable to provide consent
We found this trial at
1
site
Miami, Florida
Principal Investigator: Wendy Lee, MD
Phone: 305-326-6434
Click here to add this to my saved trials
